A phase 3, randomized, double-blind, placebo-controlled trial of the effect of motavizumab prophylaxis on reduction of the incidence of serious early childhood wheezing in preterm infants

Trial Profile

A phase 3, randomized, double-blind, placebo-controlled trial of the effect of motavizumab prophylaxis on reduction of the incidence of serious early childhood wheezing in preterm infants

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2012

At a glance

  • Drugs Motavizumab (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Jul 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
    • 04 Feb 2009 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov.
    • 21 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top